The nominating institution Hans Knöll Institute on the breakthrough:

The dramatic rise of multidrug resistant infections requires global R&D efforts. This is not only a scientific, but a global socioeconomic challenge. Since antibiotics development is not lucrative, publicly funded programs are increasingly important. Kloß’s group is developing a new antibiotic against multi-resistant tuberculosis, which kills 1.5 million every year.

Tags: Bio-Tech, Drugs, Therapeutics, Antibiotics, Antimicrobial Resistance